People on dialysis face one of the highest cardiovascular risks of any patient group. Now, a landmark international trial published in the New England Journal of Medicine has found that a simple daily fish oil supplement slashes that risk by 43% — one of the most significant breakthroughs in kidney care in years.
The PISCES trial (Protection Against Incidences of Serious Cardiovascular Events Study) enrolled 1,228 patients with kidney failure across 26 dialysis centres in Australia and Canada. Half received four grams of omega-3 fish oil daily; half received a placebo. The results, after careful follow-up, were striking.
Patients taking fish oil experienced a **43% lower rate of serious cardiovascular events** compared to placebo — including heart attack, stroke, cardiac death, and vascular-related amputations.
**Why Dialysis Patients Face Such High Cardiac Risk**
Kidney failure patients on hemodialysis are at dramatically elevated cardiovascular risk compared to the general population. The reasons are complex: accumulation of inflammatory compounds that healthy kidneys would filter out, altered lipid metabolism, and chronically low levels of omega-3 fatty acids (EPA and DHA) — the very compounds found in fish oil.
Dialysis patients typically have omega-3 levels significantly below the general population. The research team, co-led by Monash Health and Monash University in Australia, hypothesised that restoring those levels might offer cardiac protection. The trial results confirmed it dramatically.
**The Trial Results**
This was a rigorous double-blind, placebo-controlled study — the gold standard for clinical evidence. Key findings:
- **43%** reduction in serious cardiovascular events in the fish oil group - Events covered: heart attack, stroke, cardiac death, vascular amputation - Fish oil dose: 4g daily (containing 1.6g EPA and 0.8g DHA) - 1,228 participants, 26 sites, two countries - Results presented at the American Society of Nephrology Kidney Week and published in NEJM
The research team noted that 'few therapies have been shown to reduce cardiovascular risk in this high-risk patient group' — making the finding all the more significant. Cardiovascular disease is the leading cause of death in dialysis patients worldwide.
**What This Means for Patients**
For the 3.4 million people globally who receive dialysis for kidney failure, this finding is highly significant. Omega-3 supplementation is safe, inexpensive, widely available, and has essentially no serious side effects at these doses. Implementation across dialysis networks could potentially save tens of thousands of lives annually.
Researchers are careful to note that these findings apply specifically to hemodialysis patients — the mechanisms driving the benefit are linked to the specific metabolic state of kidney failure, and should not be generalised to healthy adults.
**A Supplement That Finally Proved Its Worth**
Omega-3 supplementation has been a topic of sometimes-contradictory research. Trials in healthy populations have shown mixed results. What the PISCES trial demonstrates is that in a specific high-risk population with known omega-3 deficiency, the supplementation has a large and measurable protective effect.
The trial represents over a decade of work by the Australian research team. Its publication in the New England Journal of Medicine — the world's most prestigious medical journal — signals that the nephrology community regards this finding as both credible and practice-changing.
For patients undergoing dialysis, and for the clinicians who care for them, it is a genuinely hopeful result. ❤️
*Sources: New England Journal of Medicine, Monash Health, MirageNews, ScienceDaily, Physicians Weekly, TCTMD*
